[Federal Register Volume 60, Number 144 (Thursday, July 27, 1995)]
[Notices]
[Pages 38576-38577]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 95-18407]



-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[DEA #134P]


Controlled Substances: Proposed Aggregate Production Quotas for 
1996

AGENCY: Drug Enforcement Administration (DEA), Justice.

ACTION: Notice of proposed aggregate production quotas for 1996.

-----------------------------------------------------------------------

SUMMARY: This notice proposes initial 1996 aggregate production quotas 
for controlled substances in Schedules I and II of the Controlled 
Substances Act.

DATES: Comments or objections should be received on or before August 
28, 1995.

ADDRESSES: Send comments or objections to the Deputy Administrator, 
Drug Enforcement Administration, Washington, DC 20537, Attn: DEA 
Federal Register Representative (CCR).

FOR FURTHER INFORMATION CONTACT:
Howard McClain, Jr., Chief, Drug & Chemical Evaluation Section, Drug 
Enforcement Administration, Washington, D.C. 20537, Telephone: (202) 
307-7183.

SUPPLEMENTARY INFORMATION: Section 306 of the Controlled Substances Act 
(21 U.S.C. 826) requires that the Attorney General establish aggregate 
production quotas for each basic class of controlled substance listed 
in Schedules I and II. This responsibility has been delegated to the 
Administrator of the DEA by Section 0.100 of Title 28 of the Code of 
Federal Regulations.
    The Administrator, in turn, has redelegated this function to the 
Deputy Administrator pursuant to Sec. 0.104 of Title 28 of the Code of 
Federal Regulations.
    The quotas are to provide adequate supplies of each substance for: 
(1) The estimated medical, scientific, research, and industrial needs 
of the United States; (2) lawful export requirements; and (3) the 
establishment and maintenance of reserve stocks.
    In determining the below listed proposed 1996 aggregate production 
quotas, the Deputy Administrator considered the following factors: (1) 
Total actual 1994 and estimated 1995 and 1996 net disposals of each 
substance by all manufacturers; (2) estimates of 1995 year-end 
inventories of each substance and of any substance manufactured from it 
and trends in accumulation of such inventories; and (3) projected 
demand as indicated by procurement quota applications filed pursuant to 
Sec. 1303.12 of title 21 of the Code of Federal Regulations.
    Pursuant to Sec. 1303.23(c) of title 21 of the Code of Federal 
Regulations, the Deputy Administrator of the DEA will, in early 1996, 
adjust aggregate production quotas and individual manufacturing quotas 
allocated for the year based upon 1995 year-end inventory and actual 
1995 disposition data supplied by quota recipients for each basic class 
of Schedule I or II controlled substance.
    Therefore, under the authority vested in the Attorney General by 
section 306 of the Controlled Substances Act of 1970 (21 U.S.C. 826), 
delegated to the Administrator of the DEA by Sec. 0.100 of title 28 of 
the Code of Federal Regulations, and redelegated to the Deputy 
Administrator pursuant to Sec. 0.104 of title 28 of the Code of Federal 
Regulations, the Deputy Administrator hereby proposes that the 
aggregate production quotas for 1996 for the following controlled 
substances, expressed in grams of anhydrous acid or base, be 
established as follows:

------------------------------------------------------------------------
                                                               Proposed 
                        Basic class                          1996 quotas
------------------------------------------------------------------------
Schedule I:                                                             
  Acetylmethadol...........................................            7
  Alphacetylmethadol.......................................            7
  Aminorex.................................................            7
  Cathinone................................................            9
  Difenoxin................................................       14,000
  Dihydromorphine..........................................            7
  2,5-Dimethoxyamphetamine.................................   10,650,000
  Dimethylamphetamine......................................            7
  Ethylamine Analog of Phencyclidine.......................            5
  N-Ethylamphetamine.......................................            7
  Lysergic acid diethylamide...............................           58
  Mescaline................................................            7
  Methaqualone.............................................           17
  Methcathinone............................................            9
  4-Methoxyamphetamine.....................................           17
  4-Methylaminorex.........................................            2
  3,4-Methylenedioxyamphetamine............................           17
  3,4-Methylenedioxy-N-ethylamphetamine....................           27
  3,4-Methylenedioxymethamphetamine........................           42
  3-Methylfentanyl.........................................           14

[[Page 38577]]
                                                                        
  Normethadone.............................................            7
  Normorphine..............................................            7
  Psilocybin...............................................            2
  Psilocyn.................................................            2
  Tetrahydrocannibinols....................................       55,100
Schedule II:                                                            
  Alfentanil...............................................        8,500
  Amobarbital..............................................           15
  Amphetamine..............................................    1,300,100
  Cocaine..................................................      550,040
  Codeine (for sale).......................................   58,395,000
  Codeine (for conversion).................................   16,632,000
  Desoxyephedrine, 1,000,000 grams of levodesoxyephedrine               
   for use in a noncontrolled, nonprescription product and              
   44 kg for methamphetamine...............................    1,044,000
  Dextropropoxyphene.......................................  118,066,000
  Dihydrocodeine...........................................       60,000
  Diphenoxylate............................................    1,063,000
  Ecgonine (for conversion)................................      650,100
  Ethylmorphine............................................           12
  Fentanyl.................................................      120,100
  Hydrocodone (for sale)...................................    8,880,000
  Hydrocodone (for conversion).............................    2,800,000
  Hydromorphone............................................      448,000
  Isomethadone.............................................           12
  Levo-alpha-acetylmethadol................................      200,000
  Levorphanol..............................................       14,300
  Meperidine...............................................   10,822,000
  Methadone................................................    4,551,000
  Methadone (for conversion)...............................      364,000
  Methadone Intermediate (for conversion)..................    5,534,000
  Methamphetamine (for conversion).........................      723,000
  Methylphenidate..........................................   10,291,000
  Morphine (for sale)......................................   12,450,000
  Morphine (for conversion)................................   76,735,000
  Noroxymorphone (for sale)................................        2,000
  Noroxymorphone (for conversion)..........................    2,406,000
  Opium....................................................    1,226,000
  Oxycodone (for sale).....................................    5,571,000
  Oxycodone (for conversion)...............................       37,300
  Oxymorphone..............................................       11,200
  Pentobarbital............................................   15,100,000
  Phencyclidine............................................           40
  Phenylacetone (for conversion)...........................    5,280,000
  1-Phenylcyclohexylamine..................................           10
  1-Piperidinocyclohexanecarbonitrile......................           12
  Secobarbital.............................................      400,000
  Sufentanil...............................................        1,000
  Thebaine.................................................    9,217,000
------------------------------------------------------------------------


    The Deputy Administrator further proposes that aggregate production 
quotas for all other Schedules I and II controlled substances included 
in Secs. 1308.11 and 1308.12 of title 21 of the Code of Federal 
Regulations be established at zero.
    All interested persons are invited to submit their comments and 
objections in writing regarding this proposal. A person may object to 
or comment on the proposal relating to any of the above-mentioned 
substances without filing comments or objections regarding the others. 
If a person believes that one or more of these issues warrant a 
hearing, the individual should so state and summarize the reasons for 
this belief.
    In the event that comments or objections to this proposal raise one 
or more issues which the Deputy Administrator finds warrant a hearing, 
the Deputy Administrator shall order a public hearing by notice in the 
Federal Register, summarizing the issues to be heard and setting the 
time for the hearing.
    The Office of Management and Budget has determined that notices of 
aggregate production quotas are not subject to centralized review under 
Executive Order 12866. This action has been analyzed in accordance with 
the principles and criteria contained in Executive Order 12612, and it 
has been determined that this matter does not have sufficient 
federalism implications to warrant the preparation of a Federalism 
Assessment.
    The Deputy Administrator hereby certifies that this action will 
have no significant impact upon small entities whose interests must be 
considered under the Regulatory Flexibility Act, 5 U.S.C. 601, et seq. 
The establishment of annual aggregate production quotas for Schedules I 
and II controlled substances is mandated by law and by international 
treaty obligations. While aggregate production quotas are of primary 
importance to large manufacturers, their impact upon small entities is 
neither negative nor beneficial. Accordingly, the Deputy Administrator 
has determined that this action does not require a regulatory 
flexibility analysis.

    Dated: July 19, 1995.
Stephen H. Greene,
Deputy Administrator.
[FR Doc. 95-18407 Filed 7-26-95; 8:45 am]
BILLING CODE 4410-09-M